On Jan. 30, 2025, the California Institute for Regenerative Medicine (CIRM) announced it has awarded nearly $100 million to fund various projects from its Discovery, Translational, and Clinical programs.

“CIRM remains deeply committed to accelerating stem cell and gene therapies for patients in need,” said Rosa Canet-Avilés, PhD, Chief Science Officer at CIRM. “We are excited to support these groundbreaking projects, advancing research from discovery to clinical impact across neurological, psychiatric, cardiovascular, blood, and cancer-related diseases, as well as chronic pain.”

Among the awards are two preclinical projects (CLIN1) and two clinical trials (CLIN2) in the Agency’s clinical program, which provides funding for eligible stem cell and gene therapy-based projects through all stages of clinical trial development.